We report the development of a new combinatorial approach that allows for peptide-mediated selective tissue targeting of nuclear hormone pharmacology while eliminating adverse effects in other tissues. Specifically, we report the development of a glucagon-like peptide-1 (GLP-1)-estrogen conjugate that has superior sex-independent efficacy over either of the individual hormones alone to correct obesity, hyperglycemia and dyslipidemia in mice. The therapeutic benefits are driven by pleiotropic dual hormone action to improve energy, glucose and lipid metabolism, as shown by loss-of-function models and genetic action profiling. Notably, the peptide-based targeting strategy also prevents hallmark side effects of estrogen in male and female mice, such as reproductive endocrine toxicity and oncogenicity. Collectively, selective activation of estrogen receptors in GLP-1–targeted tissues produces unprecedented efficacy to enhance the metabolic benefits of GLP-1 agonism. This example of targeting the metabolic syndrome represents the discovery of a new class of therapeutics that enables synergistic co-agonism through peptide-based selective delivery of small molecules. Although our observations with the GLP-1–estrogen conjugate justify translational studies for diabetes and obesity, the multitude of other possible combinations of peptides and small molecules may offer equal promise for other diseases.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Grundy, S.M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat. Rev. Drug Discov. 5, 295–309 (2006).
Roth, J.D. et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl. Acad. Sci. USA 105, 7257–7262 (2008).
Müller, T.D. et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J. Pept. Sci. 18, 383–393 (2012).
Drucker, D.J. The biology of incretin hormones. Cell Metab. 3, 153–165 (2006).
Barrera, J.G., Sandoval, D.A., D'Alessio, D.A. & Seeley, R.J. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nature reviews. Endocrinology 7, 507–516 (2011).
Cvetković, R.S. & Plosker, G.L. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 67, 935–954 (2007).
Davies, M.J., Kela, R. & Khunti, K. Liraglutide—overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes. Metab. 13, 207–220 (2011).
Amori, R.E., Lau, J. & Pittas, A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. J. Am. Med. Assoc. 298, 194–206 (2007).
Talsania, T., Anini, Y., Siu, S., Drucker, D.J. & Brubaker, P.L. Peripheral exendin-4 and peptide YY3–36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 146, 3748–3756 (2005).
Williams, D.L., Baskin, D.G. & Schwartz, M.W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 55, 3387–3393 (2006).
Day, J.W. et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5, 749–757 (2009).
Mauvais-Jarvis, F. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol. Metab. 22, 24–33 (2011).
Musatov, S. et al. Silencing of estrogen receptor α in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. Proc. Natl. Acad. Sci. USA 104, 2501–2506 (2007).
Gao, Q. et al. Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals. Nat. Med. 13, 89–94 (2007).
Gao, Q. & Horvath, T.L. Cross-talk between estrogen and leptin signaling in the hypothalamus. Am. J. Physiol. Endocrinol. Metab. 294, E817–E826 (2008).
Xu, Y. et al. Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. Cell Metab. 14, 453–465 (2011).
Nilsson, S., Koehler, K.F. & Gustafsson, J.A. Development of subtype-selective oestrogen receptor-based therapeutics. Nat. Rev. Drug Discov. 10, 778–792 (2011).
Patterson, J.T. et al. A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. ACS Chem. Biol. 6, 135–145 (2011).
Adelhorst, K., Hedegaard, B.B., Knudsen, L.B. & Kirk, O. Structure-activity studies of glucagon-like peptide-1. J. Biol. Chem. 269, 6275–6278 (1994).
Bryzgalova, G. et al. Mechanisms of antidiabetogenic and body weight-lowering effects of estrogen in high-fat diet–fed mice. Am. J. Physiol. Endocrinol. Metab. 295, E904–E912 (2008).
Inoue, S. et al. Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc. Natl. Acad. Sci. USA 90, 11117–11121 (1993).
Papageorgiou, A. & Denef, C. Estradiol induces expression of 5-hydroxytryptamine (5-HT) 4, 5–HT5, and 5–HT6 receptor messenger ribonucleic acid in rat anterior pituitary cell aggregates and allows prolactin release via the 5–HT4 receptor. Endocrinology 148, 1384–1395 (2007).
Jankowski, M., Rachelska, G., Donghao, W., McCann, S.M. & Gutkowska, J. Estrogen receptors activate atrial natriuretic peptide in the rat heart. Proc. Natl. Acad. Sci. USA 98, 11765–11770 (2001).
Lee, K. et al. Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer. BMC Cancer 8, 158 (2008).
Bjerre Knudsen, L. et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151, 1473–1486 (2010).
Cho, M.A. et al. Expression and role of estrogen receptor α and β in medullary thyroid carcinoma: different roles in cancer growth and apoptosis. J. Endocrinol. 195, 255–263 (2007).
Le May, C. et al. Estrogens protect pancreatic β-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc. Natl. Acad. Sci. USA 103, 9232–9237 (2006).
Liu, S. et al. Importance of extranuclear estrogen receptor-α and membrane G protein–coupled estrogen receptor in pancreatic islet survival. Diabetes 58, 2292–2302 (2009).
Tiano, J.P. et al. Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents β cell failure in rodent models of type 2 diabetes. J. Clin. Invest. 121, 3331–3342 (2011).
Wong, W.P. et al. Extranuclear estrogen receptor-α stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proc. Natl. Acad. Sci. USA 107, 13057–13062 (2010).
Shughrue, P.J., Askew, G.R., Dellovade, T.L. & Merchenthaler, I. Estrogen-binding sites and their functional capacity in estrogen receptor double knockout mouse brain. Endocrinology 143, 1643–1650 (2002).
Park, C.J. et al. Genetic rescue of nonclassical ERα signaling normalizes energy balance in obese Erα-null mutant mice. J. Clin. Invest. 121, 604–612 (2011).
Revankar, C.M., Cimino, D.F., Sklar, L.A., Arterburn, J.B. & Prossnitz, E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307, 1625–1630 (2005).
Mårtensson, U.E. et al. Deletion of the G protein–coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 150, 687–698 (2009).
Son, S. et al. Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid–modified long-acting exendin-4 derivatives. J. Med. Chem. 52, 6889–6896 (2009).
Harrington, W.R. et al. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol. Endocrinol. 20, 491–502 (2006).
Krop, I.E. et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28, 2698–2704 (2010).
Erickson, H.K. et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66, 4426–4433 (2006).
López, M. et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat. Med. 16, 1001–1008 (2010).
Thaler, J.P. et al. Obesity is associated with hypothalamic injury in rodents and humans. J. Clin. Invest. 122, 153–162 (2012).
We thank D. Smiley and J. Levy for assistance in peptide synthesis, purification and characterization; J. Patterson and J. Day for their contribution to optimizing the peptide sequences; J. Ford for cell culture maintenance; J. Gidda and S. Vignati for their expert advice on pharmacology studies; and Y.-X. Li (Medpace Bioanalytical Labs) for assistance with in vivo pharmacokinetic studies. Partial research funding was provided by Marcadia Biotech, which has been acquired by Roche Pharma.
The authors declare no competing financial interests.
About this article
Cite this article
Finan, B., Yang, B., Ottaway, N. et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat Med 18, 1847–1856 (2012). https://doi.org/10.1038/nm.3009
Trends in Pharmacological Sciences (2021)
Molecular Metabolism (2021)
Antioxidants & Redox Signaling (2021)
The FEBS Journal (2021)
Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell
Journal of the American Chemical Society (2021)